
In a phase 3 clinical trial in China, recombinant human prourokinase (rhPro-UK), a thrombolytic agent, was tested on 663 patients with acute ischemic stroke (AIS) within 4.5 hours of onset, compared to alteplase. Results revealed rhPro-UK was noninferior, with similar positive outcomes on the modified Rankin Scale at 90 days. Symptomatic intracerebral hemorrhage and systemic bleeding were low, favoring rhPro-UK over alteplase. Thrombolysis-related deaths were comparable in both groups. The study concludes that intravenous rhPro-UK is a viable alternative to alteplase for AIS treatment, offering similar efficacy with potentially fewer bleeding complications.
Like
Save
Share